Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D James, Matthew R Sydes, Noel W Clarke et al. · 2016
Read Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial by Nicholas D James, Matthew R Sydes, Noel W Clarke et al. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-4800035.txt.
Description
James, Sydes, Clarke, and their co-authors reported survival results from the STAMPEDE trial in 2016. For decades, going back to the 1940s, long-term hormone therapy was the standard care when prostate cancer had spread. STAMPEDE tested whether adding other treatments at the start would help men live longer.
The trial used an adaptive multiarm, multistage platform design and recruited men with high-risk or spreading disease. Arms added docetaxel chemotherapy, zoledronic acid, or both to hormone therapy. Platform designs test several questions in one trial, saving years over separate studies. STAMPEDE's results changed first-line care for advanced prostate cancer in many countries.
Catalog record
| CREATOR | Nicholas D James, Matthew R Sydes, Noel W Clarke et al. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PubMed Central |